Assessing Risk of Progression in Barrett's Esophagus Using a Mass-Spectrometry-Based Proteomic Panel
The promising performance of the model generated here suggests that the test may aid in selecting patients most likely to benefit from active BE surveillance. Moreover, the association of this model's prediction with time-to-progression may offer decision support for management of patients likely to progress quickly. These results support continued development of this proteomic panel as a risk stratification tool for patients with BE.
Authors
- Rofyda Elhalaby (ORCID: https://orcid.org/0000-0001-6990-8154)
- Catherine E. Hagen (ORCID: https://orcid.org/0000-0002-1867-4957)
- Sheeno Thyparambil (ORCID: https://orcid.org/0000-0002-3230-8785)
- Andrew Cannon (ORCID: https://orcid.org/0000-0002-5892-8907)
- Joe Abdo (ORCID: https://orcid.org/0000-0002-1463-9038)
- Christopher Hartley (ORCID: https://orcid.org/0000-0002-2237-3102)
- Igor Ban (ORCID: https://orcid.org/0009-0007-0407-4989)
Institutions
- Mayo Clinic (US)
- Garden City Community College (US)
- Microprobes (United States) (US)
- Mayo Clinic in Florida (US)
- BioFire Diagnostics (United States) (US)
Publication Details
- Journal
- Clinical and Translational Gastroenterology
- Published
- 2025-10-24
- DOI
- https://doi.org/10.14309/ctg.0000000000000939
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00